FUNDING

Verily current investors, include Alphabet, Silver Lake, Temasek, Ontario Teachers’ Pension Plan and others.

Pacific6 is an investment partnership founded, in part, by John Molina, the former CFO of Molina Healthcare. His brother, J. Mario Molina, M.D., former CEO of Molina Healthcare, is the principal behind JM Molina Investments.

With nearly 700 million people infected with a mosquito-borne disease every year, as well as the increase in mosquito populations driven by a warming climate, it is a massive and growing challenge to fight them using only traditional approaches.

The funds raised will be used to promote the further geographical expansion of osteolabs GmbH in the Scandinavian countries, the BENELUX countries, Switzerland and Austria.

The investor syndicate includes Rev1 Ventures, Broadview Ventures, and Viva BioInnovator. Concurrent with the financing, Ryan Helon of Rev1, Thomas Needham of Broadview, and Dr. Dan Meyers have joined Basking’s Board of Directors.

The two organisations will use the funds to accelerate the discovery of novel therapeutic and diagnostic antibodies with validated anti-infective properties against COVID-19. Building on strong scientific knowhow, a new antibody development platform will be created that will help realise the vision of producing a breakthrough therapeutic that directly targets SARS-CoV-2.

Kayentis is active in the global electronic Clinical Outcome Assessment (eCOA) market, which is expected to reach $2.6 billion by 2027. Market growth in eCOA – a method of capturing outcomes data electronically in clinical trials – is driven by the clinical trials industry.

To undertake a large-scale, systematic investigation of the brain circuits and mechanisms that are responsible for triggering psychiatric symptoms in Parkinson's disease.